GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

MHRA’s independence also questioned during Commons debate, with regulator accused of being too close to companies it ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

Ischemic stroke market Insights: Rising prevalence of ischemic strokes boosts demand for effective treatment and prevention strategies.

The announcement that CMC Motors Group will be shutting down has rekindled concerns about the state of Kenya’s business ...

Kassa and others said Big Pharma continues to invest even as private equity funds have pulled back. He noted ...

GSK PLC GSK shares inched down 0.37% to £13.54 Monday, on what proved to be an all-around favorable trading session for the ...

Swiss biopharma company BioVersys said on Tuesday it plans to list on the Swiss stock exchange in the first quarter with an initial public offering that aims to raise around 80 million Swiss francs ...

European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0 ...

European regulators have expanded the usage of GSK's Jemperli drug for endometrial cancer, the pharmaceutical firm announced ...

GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...